Current prospects for gene therapy of cystic fibrosis

Area of Science:

• Biomedical Engineering
• Gene Therapy
• Respiratory Medicine

Background:

• Conventional cystic fibrosis (CF) therapies improve survival but are not curative.
• Gene therapy holds promise for correcting CF defects but is limited by delivery efficiency, duration, and safety concerns.
• Current viral vectors face challenges with cell access and host immunity, hindering re-administration.

Purpose of the Study:

• To review advancements in viral and non-viral gene therapy vectors for cystic fibrosis.
• To identify key challenges and potential solutions for effective gene delivery in CF.

Main Methods:

• Review of current literature on gene therapy vectors for cystic fibrosis.
• Analysis of viral vector strategies (immune evasion, serotype modification, retargeting).
• Evaluation of non-viral vector improvements (naked DNA, lipid-based, molecular conjugates, polymers).

Main Results:

• Viral vectors are being engineered for better immune evasion and cell targeting.
• Non-viral vectors show promise, particularly polymer-based and molecular conjugates, for transfecting non-dividing cells.
• Significant improvements in vector stability, safety, and efficacy are needed for clinical translation.

Conclusions:

• Further development of both viral and non-viral vectors is crucial for achieving curative gene therapy in cystic fibrosis.
• Overcoming immune responses and improving delivery efficiency are key areas for future research.
• Stable, safe, and re-administrable vectors are essential for successful long-term CF gene therapy.